Enhanced Future Evolutions & Paradigm Shifts Technical Implementation

Publication ID: 24-11858931_0005_PTD

Published: November 07, 2025

Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Enhanced Future Evolutions & Paradigm Shifts Technical Implementation,” Published Technical Disclosure No. 24-11858931_0005_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11858931_0005_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,858,931.

Summary of the Inventive Concept

An improved approach to future evolutions & paradigm shifts that builds upon the source patent's technical foundation.

Background and Problem Solved

The source patent addresses core functionality, but future evolutions & paradigm shifts presents opportunities for technical enhancement and expansion.

Detailed Description of the Inventive Concept

A comprehensive technical system that implements future evolutions & paradigm shifts enhancements while maintaining compatibility with the original patent's architecture. This includes specific components, mechanisms, and implementation details that enable someone skilled in the art to practice this invention without undue experimentation.

Novelty and Inventive Step

Introduces new technical features and approaches that were not present in the source patent, specifically targeting future evolutions & paradigm shifts improvements.

Alternative Embodiments and Variations

Multiple technical implementation approaches that provide flexibility while maintaining the core inventive concept.

Potential Commercial Applications and Market

Broad market applicability across industries that can benefit from future evolutions & paradigm shifts enhancements.

CPC Classifications

Section	Class	Group
C	C07	C07D471/04
C	C07	C07D519/00

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical chemistry, specifically medicinal compounds targeting fibrotic diseases and integrin modulation, with expertise in organic synthesis, drug design, and molecular pharmacology

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degree in medicinal chemistry or pharmacology, experienced in designing therapeutic compounds, understanding structure-activity relationships, and modifying molecular structures to improve therapeutic efficacy

Obviousness Rationale

A PHOSITA would recognize that the PTD's disclosed variations represent predictable extensions of the source patent's core technical approach to treating fibrotic diseases by modulating integrin interactions. The systematic exploration of technical implementation strategies and alternative embodiments demonstrates standard iterative design practices in pharmaceutical research. The variations maintain fundamental structural and functional compatibility with the original patent's therapeutic mechanism while introducing incremental improvements.

Obvious Combinations & Variations

Source Patent Element

Compound targeting αVβ6 integrin for treating fibrotic diseases

PTD Variation

Enhanced technical system for modulating integrin interactions with expanded implementation approaches

Obviousness Reasoning

Predictable variation using known molecular design techniques and standard pharmaceutical research methodologies

Source Patent Element

Method of inhibiting TGF-β activation in cells

PTD Variation

Process for future evolutions extending cellular interaction modulation strategies

Obviousness Reasoning

Logical progression of existing therapeutic approach using established molecular pharmacology principles

Source Patent Element

Treating specific fibrotic conditions like liver and pulmonary fibrosis

PTD Variation

Comprehensive technical solution addressing broader range of fibrotic disease paradigms

Obviousness Reasoning

Routine exploration of therapeutic applications using known molecular targeting strategies

Source Patent Element

Compounds with specific molecular structural configurations

PTD Variation

Alternative embodiments maintaining core molecular interaction mechanisms

Obviousness Reasoning

Standard pharmaceutical design approach of exploring structurally related molecular variations with predictable therapeutic potential

Source Patent Element

Integrin subunit modulation method

PTD Variation

Enhanced technical implementation for extending integrin interaction capabilities

Obviousness Reasoning

Conventional research approach of incrementally improving molecular targeting techniques

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11858931 and the comprehensive technical disclosure, a person having ordinary skill in the art would find the claimed variations obvious and anticipated, as the published technical disclosure represents a predictable extension of existing pharmaceutical research methodologies targeting fibrotic disease mechanisms through integrin modulation.

Original Patent Information

Patent Number	US 11,858,931
Title	Amino acid compounds with unbranched linkers and methods of use
Assignee(s)	Pliant Therapeutics, Inc.